A potential new treatment for CDKL5 deficiency disorder
- PMID: 35429468
- DOI: 10.1016/S1474-4422(22)00127-2
A potential new treatment for CDKL5 deficiency disorder
Conflict of interest statement
DG has received honoraria and speakers fees from UCB, BioMarin, and Eisai.
Comment on
-
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.Lancet Neurol. 2022 May;21(5):417-427. doi: 10.1016/S1474-4422(22)00077-1. Lancet Neurol. 2022. PMID: 35429480 Clinical Trial.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources